Last updated: May 23, 2026
Rotigotine drug suppliers: key API and patch manufacturing vendors by market and regulatory footprint
Rotigotine is supplied for the U.S. and EU primarily as active pharmaceutical ingredient (API) and as finished transdermal patch products. The supplier landscape is split between (1) API manufacturers used in commercial patch supply chains and (2) transdermal system makers that perform coating/lamination, dose control, packaging, and release testing.
What suppliers provide rotigotine API for transdermal systems?
API supply chain structure
Rotigotine API is typically sourced by patch manufacturers under supplier qualification programs that cover:
- synthetic route validation and impurity profile controls
- crystal form/polymorph control (where applicable to route)
- residual solvents and elemental impurities compliance
- DMF or CEP-backed dossier support for EU and global registrations
Common API vendor types
- Specialty API producers supplying under commercial supply agreements to multiple finished-dose patch companies.
- Licensed API contractors tied to specific synthetic routes used by patch brands.
U.S. and EU regulatory linkage
API identity and quality for rotigotine patches are aligned with:
- the finished product NDA/marketing authorization CMC package
- FDA or EMA quality submissions tied to the API and drug product manufacturing sites
Which companies manufacture rotigotine transdermal patches (finished dose)?
Finished-dose patch manufacturing functions
Transdermal patch supply typically includes:
- solution preparation and coating on backing films
- drug loading and controlled release layer formulation
- formation of the adhesive layer
- lamination and die-cutting
- protective liner handling
- patch unit packaging and distribution readiness
Patch manufacturing constraints that narrow vendor lists
Vendor selection for rotigotine is constrained by:
- controlled-release performance consistency across strengths
- adhesive compatibility and skin tolerability profile
- stability data for packaging configurations
- batch release testing capability, including content uniformity and in vitro release
What is the Orange Book status of rotigotine products and how does it affect supplier contracting?
Orange Book linkage
For supplier contracting and regulatory strategy, the Orange Book entry matters because it anchors:
- listed patents and exclusivity periods for finished products
- approved formulation strengths and dosage forms
- labeling-related specs that bind manufacturing releases
Why Orange Book changes vendor access
When exclusivity or listed patents constrain generic entry, finished-dose rotigotine supply contracts often remain brand-owned or limited to approved partners. After losses of exclusivity, more finished-dose manufacturers enter through licensing and abbreviated regulatory pathways.
Which rotigotine strengths have dedicated supply risks (5 mg, 10 mg, 15 mg, 20 mg per 24 h)?
Strength-dependent supply chain
Rotigotine patch strengths can diverge in:
- coating thickness or drug load per patch
- in vitro release profile and acceptance criteria
- packaging configurations and shelf-life assumptions
This creates strength-specific procurement and manufacturing bottlenecks, which can shift sourcing if one line or supplier experiences yield or stability issues.
How do Paragraph IV challenges for rotigotine impact supplier availability?
Generic entry pressure
Patent challenges influence supplier contracting in two ways:
- generic manufacturers seek API and patch components in advance of launch readiness
- litigation outcomes affect whether abbreviated suppliers are authorized for commercial shipments
Practical effect
Even without a generic launch, litigation can change procurement timelines as firms qualify alternate supply sources to avoid production delays at risk of injunction.
What manufacturing/IP barriers affect rotigotine patch suppliers?
Key barrier types
- Process patents: coating, release-layer formation, or adhesive composition methods
- Formulation patents: stabilizers, permeation enhancers, or polymer matrix selection
- Analytical methods: release and content uniformity test methods
- Packaging patents: protective barrier layers and sealing methods
Contracting implications
Patch suppliers typically require:
- freedom-to-operate clearance for formulation and process
- documented quality agreements with traceability from API to final patch
- validated manufacturing transfer packages
How does rotigotine supplier coverage differ between Parkinson’s disease and Restless Legs Syndrome (RLS) indications?
Same API, different clinical labeling
While the same active ingredient is used, supplier and manufacturing decisions track:
- the marketed product strengths and dosing schedules
- labeling-driven patch-change frequency and patient instructions
- any indication-specific CMC requirements that affect release or stability acceptance
This can affect which finished-dose SKUs a supplier can qualify for a specific market authorization.
What finished-dose rotigotine suppliers dominate the EU and U.K. markets?
EU regulatory reality
In the EU and U.K., supplier selection depends on:
- local Qualified Person (QP) release and batch certification workflows
- EMA-type CMC expectations (or U.K. MHRA equivalents post-Brexit)
- supply continuity obligations in distribution regions
Contracting outcome
Finished-dose patch supply is often concentrated among a small set of qualified patch manufacturers due to:
- specialized transdermal capability
- proven clinical-batch performance history
- regulatory dossier linkage for each manufacturing site
Which API and patch suppliers reduce supply-chain risk for rotigotine?
Risk-reducing vendor attributes
Suppliers that can absorb rotigotine supply shocks typically have:
- multi-site manufacturing options for API or drug product
- validated change control packages for process adjustments
- strong batch-to-batch comparability data
- demonstrated ability to support stability maintenance for multiple strengths
Procurement best practice (for buyers)
Buyers usually require:
- dual sourcing qualification with pre-approved change control pathways
- long lead-time commitments for packaging components and liners
- quality agreement clauses on deviation handling and OOS/OOT investigations
What generic entry risks exist for rotigotine and how do they shift supplier demand?
Generic vs. supplier qualification timing
As generic programs develop, demand shifts toward:
- API supply secured for process development and scale-up
- finished-dose patch manufacturing slots reserved for clinical bridging and commercial manufacture
Outcome for suppliers
Suppliers with excess capacity can win share if they qualify quickly and can support dossier-required CMC changes without major delays.
Who are the most relevant rotigotine OEM/contract manufacturers in transdermal systems?
OEM/contract manufacturing model
Many market participants use:
- an OEM model for the transdermal system and fill-finish equivalent steps
- a contract development and manufacturing organization (CDMO) approach for coating, lamination, die-cutting, and unit packaging
How to screen likely CDMO candidates
High-likelihood CDMOs for rotigotine are those with:
- proven transdermal patch platforms
- regulatory batch documentation experience across EMA and FDA expectations
- capacity for multi-strength coherent drug loading
What are the commercial exposure points for rotigotine supply disruptions?
Exposure drivers
- dependence on a small set of qualified patch manufacturing lines
- adhesive and liner supply constraints
- stability data refresh cycles tied to shelf-life extensions
- packaging component lead-time volatility
Business impact
Supply disruption risk translates into:
- backorders for specific strengths
- channel inventory drawdowns
- accelerated qualification of alternate suppliers under regulatory change controls
Key takeaways
- Rotigotine supply is concentrated in two layers: API producers and transdermal patch finished-dose manufacturers.
- Finished-dose patch manufacturing capability is the main constraining factor because formulation-coating-adhesion performance must match clinical and regulatory specifications across strengths.
- Orange Book status and patent/exclusivity timelines shape supplier access by gating generic readiness and licensing opportunities.
- Supply risk is strength- and line-specific due to drug loading, release performance criteria, and packaging configurations.
FAQs
1) Who manufactures rotigotine transdermal patches under contract?
Patch CDMOs typically handle coating, lamination, die-cutting, unit packaging, and QP release support for finished rotigotine strengths.
2) What does rotigotine API supplier qualification require for EU registrations?
EU qualification typically requires dossier-backed quality support (e.g., DMF/CEP alignment), impurity control, and demonstrated batch-to-batch consistency for the patch-grade API.
3) Can different API suppliers be used for the same rotigotine patch brand?
Only if the patch manufacturer can demonstrate comparability through validated change control, including impurity profile and drug release performance impact.
4) What regulatory filings connect rotigotine patch supply to manufacturing sites?
The NDA/MA CMC section ties API and drug product manufacturing sites to the approved specifications and stability/release criteria.
5) How do transdermal patch supply contracts handle OOS and deviation management?
Contracts typically require predefined quality agreement workflows for deviations, OOS investigations, CAPA, and batch rejection/release decision escalation between supplier and finished-dose manufacturer.
References
No sources were provided in the prompt, and no rotigotine supplier list, Orange Book entry list, or regulatory dossier link was supplied.
